Mirtazapine Hemihydrate USP
| Catalog Number | : | CS-O-01869 |
|---|---|---|
| CAS Number | : | 61337-67-5 |
| Status | : | Available for immediate dispatch |
| Category | : | API Standards |
| Purity | : | >98% |
| Molecular Weight | : | 283.37 mol/g |
| Molecular Formula | : | C17H21N3O |
Controlled Substance
ssThis product is under final analysis
This compound is currently under final analysis and hence the price is not available online.
You will receive an email from our team within 12 hours with the pricing and delivery information.
Shipping & Availability
| Status | : | Available for immediate dispatch |
|---|---|---|
| COA | : |
[Login Needed]
|
| MSDS | : |
[Login Needed]
|
| Controlled Substance | : | Yes |
More Information
| Synonyms | : | 5-methyl-2;5;19-triazate1(15);8;10;12;16;18-hexaene hydrate;Mirtazapine Hemihydrate. |
|---|---|---|
| Payment mode | : | Credit / Debit / Purchase Order |
| Taxes | : | All prices are inclusive taxes |
| Refund Policy | : | 30 days money back guarantee |
| Canonical SMILES | : | CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4 |
| Isomeric SMILES | : | CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4 |
| InChI | : | InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 |
| InchIKey | : | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| IUPAC Name | : | 5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene |
| Exact Mass | : | 265.157897619 |
| Melting Point | : | 114-116 °C |
| Solubility | : | slightly soluble in water |
| Use Classification | : | Veterinary drugs -> Mirataz -> EMA Drug Category |
| Hazard Class | : | Acute Tox. 4 (100%) |
| Description | : | Mirtazapine is a benzazepine and a tetracyclic antidepressant. It has a role as an alpha-adrenergic antagonist, a serotonergic antagonist, a histamine antagonist, an anxiolytic drug, a H1-receptor antagonist and a oneirogen. |
| EC Number | : | 288-060-6 |
| Toxicity Summary | : | **LD50** Oral LD50 was 830 mg/kg in male Swiss mice 24 hours after being administered mirtazapine. **Overdose information** Activated charcoal should be administered during an overdose to absorb excess mirtazapine. General supportive therapy should be employed, including maintenance of an adequate airway, oxygen therapy, and ventilation therapy. Vital signs and cardiac rhythm must be monitored. It is not advisable to induce vomiting. Gastric lavage with a large-bore orogastric tube with proper protection of the airway is recommended. There is no antidote for mirtazapine available currently. Consider the possibility of mirtazapine combined with other drugs in an overdose and ensure to contact the local poison control center for guidance on management. **Carcinogenesis** At higher than normal doses, mirtazapine increased the incidence of hepatocellular adenomas and carcinomas in male mice. The highest doses administered to the mice were about 20 and 12 times the maximum recommended human dose (MRHD). Hepatocellular tumors and thyroid follicular adenoma/cystadenomas in male rats occurred at an increased rate at a higher mirtazapine dose (60 mg/kg/day). In female rats, both the medium (20 mg/kg/day) and higher (60 mg/kg/day) doses of mirtazapine increased the rate of hepatocellular adenomas. The relevance of these findings in humans is not known at this time. **Impairment of Fertility** Mirtazapine was administered to rats at doses reaching 100 mg/kg (equivalent to 20 times the maximum recommended human dose) in a fertility study. There was no impact on mating and conception, however, there was a disturbance of reproductive (estrous) cycling at higher doses. These doses were measured to be at least 3 times the maximum recommended human dose. Loss of fetus before implantation in the uterus occurred when doses equivalent to 20 times the maximum recommended dose were administered. **Use in pregnancy** This drug is categorized as a pregnancy category C drug. No adequate studies in pregnant women have been conducted. In rats, an increased rate of post-implantation demise occurred with mirtazapine administration. Additionally, an increase in deaths of rat pups during the first 3 days of lactation with a decrease in pup birth weight was noted. Studies on animals are not always relevant to human response. Mirtazapine should be used during pregnancy only if the clinical need outweighs the possible risks to the fetus. **Use in nursing** Whether this drug is excreted in human milk is unknown. Many drugs are found excreted in human breast milk, therefore caution is advised if this drug is used during nursing. |
We also have the following compounds available for commercial bulk quantities
Clearsynth is a technology based, research driven enterprise with the world's largest inventory of Reference Standards & Research Chemicals. We aim to enable the research community in accelerated discovery via synthesis of complex and difficult to make compounds.
© 2022 Clearsynth - is a registered trademark and the marketing name for Clearsynth Labs and its subsidiaries worldwide. Copyright (c) 2010-2022 All rights reserved